Cart
sales@molnova.com
XL-844
CAS No. 631864-00-1
XL-844( EXEL-9844 | EXEL9844 | XL844 )
Catalog No. M15387 CAS No. 631864-00-1
A potent, specific, orally available, ATP competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameXL-844
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, specific, orally available, ATP competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.
-
DescriptionA potent, specific, orally available, ATP competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively; increases gemcitabine-induced H2AX phosphorylation, blocks Cdc25A phosphorylation, and induces premature mitotic entry; significantly enhances gemcitabine antitumor activity in a PANC-1 xenograft model.Blood Cancer Phase 1 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsEXEL-9844 | EXEL9844 | XL844
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number631864-00-1
-
Formula Weight287.323
-
Molecular FormulaC14H17N5O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN
-
Chemical Name1-[2-(3-aminopropoxy)phenyl]-3-pyrazin-2-ylurea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Riesterer O, et al. Invest New Drugs. 2011 Jun;29(3):514-22.
2. Matthews DJ, et al. Cell Cycle. 2007 Jan 1;6(1):104-10.
molnova catalog
related products
-
AZD-7762
AZD-7762 (AZD7762) is a?potent and selective inhibitor of Chk1/2 with IC50 of 5 nM.
-
PV-1019
A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM.
-
Tuvusertib
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 μΜ) with selective and potentially antitumor activity.
